ITBMed has raised up to $67 million in funding. Pablo Legorreta, the founder and CEO of Royalty Pharma, was the lead investor. Carnegie Investment Bank advised ITBMed on the transaction with Baker McKenzie providing legal advice. And, Goodwin Procter LLP was legal adviser to Pablo Legorreta. Based in Sweden, ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation and gene therapy.
Source: Press Release